| THZ1 Covalent CDK7 inhibitor,potent and selective |
Sample solution is provided at 25 µL, 10mM.
- 1. Landsverk HB, Sandquist LE, et al. "Regulation of ATR activity via the RNA polymerase II associated factors CDC73 and PNUTS-PP1." Nucleic Acids Res. 2018 Dec 12. PMID:30541148
- 2. Lin L, Huang M, et al. "Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in Ewing sarcoma in co-operation with EWS-FLI1." Nucleic Acids Res. 2018 Nov 28. PMID:30496486
- 3. Zanconato F, Battilana G, et al. "Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4." Nat Med. 2018 Oct;24(10):1599-1610. PMID:30224758
- 4. Chen D, Zhao Z, et al. "Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma." Bone Res. 2018 Apr 4;6:11. PMID:29644114
- 5. Helga B. Landsverka1, Lise E. Sandquista,et al. "Regulation of ATR activity by the RNA polymerase II phosphatase PNUTS-PP1." bioRxiv.2018.February 16. PMID:29498802
- 6. Yuan J, Jiang YY, et al. "Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma." Cancer Res. 2017 Dec 1;77(23):6614-6626. PMID:28951465
- 7. Kemp MG. "DNA damage-induced ATR kinase activation in non-replicating cells is regulated by the XPB subunit of transcription factor II-H (TFIIH). J Biol Chem." 2017 Jun 7. pii: jbc.M117.788406. PMID:28592488
- 8. Liao R, Mizzen CA. "Site-specific regulation of histone H1 phosphorylation in pluripotent cell differentiation." Epigenetics Chromatin. 2017 May 22;10:29. PMID:28539972
- 9. Francavilla C, Lupia M, et al. "Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer." Cell Rep. 2017 Mar 28;18(13):3242-3256. PMID:28355574
- 10. Posternak V, Ung MH, et al. "MYC Mediates mRNA Cap Methylation of Canonical Wnt/β-Catenin Signaling Transcripts By Recruiting CDK7 and RNA Methyltransferase." Mol Cancer Res. 2017 Feb;15(2):213-224. PMID:27899423
- 11. Harrod A, Fulton J, et al. "Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer." Oncogene. 2017 Apr 20;36(16):2286-2296. PMID:27748765
Quality Control & MSDS
- View current batch:
Chemical structure
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
| Description | THZ1 is an irreversible, potent and selective inhibitor of CDK7(cyclin-dependent kinase 7) with an IC50 value of 3.2 nM. | |||||
| Targets | CDK7 | |||||
| IC50 | 3.2 nM | |||||
| Cell experiment: [1] | |
|
Cell lines |
Jurkat and Loucy T-ALL cell lines |
|
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
|
Reaction Conditions |
72 hours IC50: 50 nM (for Jurkat cells), 0.55 nM (for Loucy T-ALL cells) |
|
Applications |
As a CDK7 inhibitor, THZ1 potently inhibited proliferation of Jurkat and Loucy T-ALL cell lines with IC50 values of 50 nM and 0.55 nM, respectively. |
| Animal experiment: [1] | |
|
Animal models |
Mice bearing KOPTK1 xenografts |
|
Dosage form |
10 mg/kg, twice daily for 29 days |
|
Applications |
THZ1 exhibited efficacy in a bioluminescent xenografted mouse model using the human T-ALL cell-line KOPTK1 when dosed twice daily at 10mg/kg. THZ1waswell tolerated at these doseswith no observable body weight loss or behavioural changes, suggesting that it caused no overt toxicity in the animals. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Kwiatkowski N, Zhang T, Rahl P B, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature, 2014, 511(7511): 616-620. |
|
THZ1 Dilution Calculator
THZ1 Molarity Calculator
| Cas No. | 1604810-83-4 | SDF | Download SDF |
| Synonyms | N/A | ||
| Chemical Name | (E)-N-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)-4-(4-(dimethylamino)but-2-enamido)benzamide | ||
| Canonical SMILES | ClC1=CN=C(N=C1C2=CNC3=CC=CC=C23)NC4=CC=CC(NC(C5=CC=C(NC(/C=C/CN(C)C)=O)C=C5)=O)=C4 | ||
| Formula | C31H28ClN7O2 | M.Wt | 566.05 |
| Solubility | ≥28.3025mg/mL in DMSO | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
THZ1 is a covalent inhibitor of CDK7 with IC50 value of 3.2nM [1].
THZ1 covalently modifies CDK7 by targeting C312 residue outside of the kinase domain, providing an unanticipated means of achieving covalent selectivity. THZ1 potently inhibits proliferation of Jurkat and Loucy T-ALL cell lines with IC50 values of 50nM and 0.55nM, respectively. In the kinase binding assay, THZ1 shows a good binding affinity with IC50 value of 3.2nM [1].
As an inhibitor of CDK7, THZ1 inhibits the phosphorylation of the C-terminal domain of RNAP polymerase II, effecting the regulation of transcription. THZ1 also inhibits the activation of the CDK proteins. It is reported to disrupt the CDK7 signalling pathways both in Jurkat cells and Loucy cells. THZ1 shows a broad-based activity with IC50 values less than 200nM in a variety of cancer cell lines. Among these cell lines, T-ALL is exceptional sensitivity to THZ1 due to the transcription effect of RUNX1 caused by THZ1 [1].
References:
[1] Nicholas Kwiatkowski, Tinghu Zhang, Peter B. Rahl et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature, 2014.